• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

The ideal dry-eye drop: Through the eyes of clnicians, patients


Given the plethora of over-the-counter and prescription approaches available for dry eye, patient and clinician agreement on the appropriate regimen is key to treatment success.

Given the plethora of over-the-counter and prescription approaches available for dry eye, patient and clinician agreement on the appropriate regimen is key to treatment success. Still, coming to that agreement can be difficult.

Five steps and the criteria for success, as seen through the eyes of patients and their physicians, follow:

1. Communication. Invariably, the most important part of dry eye treatment is clinician-patient communication.

Further confounding patient-clinician agreement upon treatment is the conundrum occurring with a mismatch in clinical signs and subjective symptoms.

Although this situation does not occur too often, it certainly isn't uncommon and it is often due to a physician missing a hint during an examination.

2. Correct diagnosis. Research into clinician perceptions of the most important diagnostic characteristics shows them to be research evidence, ease of use, and the time requirement, but careful assessment remains integral in capturing disease state.1

Examination of the eyelids is required to assess potential meibomian gland dysfunction and blepharitis, for example. Furthermore, lissamine green staining should be performed in conjunction with fluorescein staining to capture conjunctival staining in addition to keratitis.

Assessing tear break-up time also is important, because that also is a clue to the stability and quality of the patient's tear film. Beyond that, the Ocular Surface Disease Index or other patient symptoms surveys also are useful in assessing patient symptoms, especially in catching early stages of dry eye.

One of the major problems with the management of ocular surface disease is the lack of a standardized approach. Recommendations put forth in recent years demonstrate an attempt to standardize our approach to both diagnosing and monitoring ocular surface disease.2

3. Finding the best treatment. As far as treatment is concerned, a good general rule is to be more aggressive in treating patients. This emphasizes to the patient that you are taking his or her ailment seriously.

In addition, compliance often is not good, so if you are suggesting more aggressive treatment and patients do not comply with everything you suggest, they are getting more treatment than they would if you suggested a less aggressive course.

Three primary situations exist that can lead to patient-physician disagreement regarding disease severity:

4. Addressing treatment concerns. After identifying the patient's disease severity, it is important to assess patient concerns with treatment. Being empathetic and expressing a desire to hear their concerns and work with them to find a shared solution is vital to treatment success.

Research presented at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology demonstrated that the primary clinician-rated goals in treating patients with moderate to severe dry eye were maintenance and protection of the ocular surface as well as lubrication and hydration of the ocular surface. But certainly we need to tend to patients' goals in treatment as well, because these are integrally tied to patient compliance.3

For patients who complain about visual blur or visual tasking difficulty, it may be best to recommend an ocular lubricant demonstrating visual function benefit.4

For patients with more severe disease that may not respond to ocular lubricant treatment alone, prescription cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) may be added to the treatment regimen.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.